Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Chimerix Inc (CMRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7977)・商品コード:DATA904C7977
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:40
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Chimerix Inc (Chimerix) is a biopharmaceutical company that develops, discovers, and commercializes novel and oral antiviral therapeutics. The company’s brincidofovir is an oral nucleotide analog to treat dsDNA viruses, adenovirus, cytomegalovirus, BK virus and herpes simplex viruses. It also develops active compounds against malaria, influenza A and B, brincidofovir for smallpox, dengue virus and tuberculosis, brincidofovir and adenovirus, among others. Chimerix’s lipid antiviral conjugate technology is used to modify a drug molecule order that it mimics a naturally occurring phospholipid metabolite. The company provides research and development services in the areas of CMV and BK virus, influenza, norovirus, and viruses that have significant global impact and there are currently no effective treatments, antivirals are associated with known toxicities such as bone marrow suppression and renal impairment. Chimerix is headquartered in Durham, North Carolina, the US.

Chimerix Inc (CMRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Equity Offering 12
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc – Key Competitors 21
Chimerix Inc – Key Employees 22
Chimerix Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 08, 2018: Chimerix announces second quarter 2018 financial results 24
May 07, 2018: Chimerix Reports First Quarter 2018 Financial Results 26
Mar 01, 2018: Chimerix Announces Fourth Quarter and Full Year 2017 Financial Results 28
Nov 08, 2017: Chimerix Announces Third Quarter 2017 Financial Results 30
Aug 07, 2017: Chimerix Announces Second Quarter 2017 Financial Results 32
May 09, 2017: Chimerix Announces First Quarter 2017 Financial Results 33
Mar 02, 2017: Chimerix Announces Fourth Quarter and Full Year 2016 Financial Results 35
Corporate Communications 37
Mar 29, 2018: Chimerix Announces Martha J. Demski as Board Chair; Appoints New Members to Board of Directors 37
Product News 38
02/22/2017: Chimerix Announces Final Data from AdVise Trial of Brincidofovir at BMT Tandem Meetings 38
Clinical Trials 39
Jan 06, 2017: Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Chimerix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Chimerix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Chimerix Enters into Licensing Agreement with ContraVir Pharma for CMX157 10
Chimerix to Raise USD75 Million in Public Offering of Shares 12
Chimerix Completes Exercise of Over-Allotment Option for Public Offering of Shares for USD22.5 Million 13
Chimerix Raises USD122 Million in Public Offering of Shares 15
Chimerix Raises USD119.4 Million in Public Offering of Shares 17
Chimerix Completes IPO For US$118 Million 19
Chimerix Inc, Key Competitors 21
Chimerix Inc, Key Employees 22
Chimerix Inc, Subsidiaries 23

List of Figures
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Chimerix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Chimerix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7977)販売に関する免責事項を必ずご確認ください。
★調査レポート[Chimerix Inc (CMRX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆